AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04602312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation (1 x 20-minute guided audio training)
Description: Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
Study NCT02853890 — intervention group
Intervention type: OTHER
Intervention: Questionnaires during hospitalization for delivery
Description: Questionnaires during hospitalization for delivery (one questionnaire completed by doctors about different technic of analgesia and anesthesia and one questionnaire completed by women about pain, and feeling about the different techniques of analgesia and anesthesia used during delivery, eventually caesarean section or uterine revision)
Study NCT01492023 — intervention group
Intervention type: BEHAVIORAL
Intervention: neuropsychological rehabilitation
Description: attention retraining and teaching compensatory strategies as well as offering psychological support to better cope with cognitive impairments (13 times 60 minutes, once per week during 13 weeks)
Study NCT00665574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActaVisc and ActaVisc Mx Intra-articular Injection
Description: ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
Study NCT00665574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ActaVisc and ActaVisc Mx Intra-articular Injection
Description: ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
Study NCT00665574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ActaVisc and ActaVisc Mx Intra-articular Injection
Description: ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
Study NCT02934074 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00491803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: sildenafil 20 mg orally
Study NCT00491803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: sildenafil 40 mg orally
Study NCT03982186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered as medium dose (Arms 1 and 3), high dose (Arm 2), and low dose (Arm 4) as subcutaneous injection.
Study NCT03982186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for JNJ-73763989
Description: Placebo for JNJ-73763989 will be administered as subcutaneous injection.
Study NCT03982186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for JNJ-73763989
Description: Placebo for JNJ-73763989 will be administered as subcutaneous injection.
Study NCT03982186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 tablets will be administered orally.
Study NCT03982186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for JNJ-56136379
Description: Placebo for JNJ-56136379 tablets will be administered orally.
Study NCT03982186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for JNJ-56136379
Description: Placebo for JNJ-56136379 tablets will be administered orally.
Study NCT03982186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analog (NA)
Description: NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.
Study NCT03982186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nucleos(t)ide Analog (NA)
Description: NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.
Study NCT03065270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use unstable shoes Masai Barefoot Technology (MBT)
Description: Use of unstable shoes during 9 weeks, at least four hours per day.
Study NCT03065270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use conventional sport shoes
Description: Use of conventional sport shoes during 9 weeks, at least four hours per day.
Study NCT01033357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Graft, Vascular Wrap
Description: Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
Study NCT01033357 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lifespan® ePTFE Vascular Graft Only
Description: Vascular Graft only
Study NCT00567190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
Study NCT00567190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (matching pertuzumab) was administered intravenously.
Study NCT00567190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
Study NCT00567190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
Study NCT00567190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m\^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
Study NCT00567190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m\^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
Study NCT00406133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitor
Description: Daily use of a continuous glucose monitor
Study NCT04549610 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB supplementation
Description: Group taking oral HMB supplementation in a blinded capsule form.
Study NCT04549610 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Group taking oral supplementation with placebo (corn starch) in a blinded capsule form.
Study NCT00227617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.
Study NCT00227617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
Study NCT00227617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 200mg/m2 IV q2 wk on day 1 over a 2-hour period.
Study NCT00227617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 200mg/m2 IV q 2 wk on day 1 over a 2-hour period
Study NCT04424420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol oral tablet
Study NCT04424420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen oral tablet
Study NCT01826812 — intervention group
Intervention type: OTHER
Intervention: 30 minutes sustained reading
Description: The participants will be given a text to read silently in 30 minutes.
Study NCT01826812 — intervention group
Intervention type: OTHER
Intervention: Dry eye exam
Description: Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.
Study NCT01326858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.7%
Description: Treatment A
Study NCT01326858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.7%
Description: Treatment A
Study NCT01326858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.7%
Description: Treatment A
Study NCT01326858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride ophthalmic solution vehicle
Description: Treatment B, inactive ingredients used as placebo
Study NCT01326858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution vehicle
Description: Treatment B, inactive ingredients used as placebo
Study NCT01326858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution vehicle
Description: Treatment B, inactive ingredients used as placebo
Study NCT01326858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate ophthalmic solution, 0.025%
Description: Treatment C
Study NCT01326858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketotifen fumarate ophthalmic solution, 0.025%
Description: Treatment C
Study NCT01326858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen fumarate ophthalmic solution, 0.025%
Description: Treatment C
Study NCT02671032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus CI532 cochlear implant
Study NCT04424420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Sugar pill manufactured to mimic the Paracetamol and Ibuprofen.
Study NCT02359487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-HIV Risk Reduction Counseling
Description: The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
Study NCT00135005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMN107, STI571
Study NCT01921296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Description: 5 milligrams orally 2 hours before bedtime
Study NCT02083016 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation guided by conventional mapping.
Description: Substrate mapping and ablation of ventricular tachycardia.
Study NCT02083016 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation guided by ultra-high density mapping with multielectrode catheter.
Description: Substrate mapping and ablation of ventricular tachycardia.
Study NCT04029129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air filtration and building envelop modifications
Description: Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.
Study NCT00846872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GHRP-3 low dose
Description: 0.1 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
Study NCT00846872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GHRP-3 high dose
Description: 0.5 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
Study NCT00846872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5% mannitol will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
Study NCT03663686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Litapiprant Tablet
Description: Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells
Study NCT02359487 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intervention
Description: Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
Study NCT04058093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Training Program
Description: Functional training program (FTP) include:~1. Functional training sessions will be oriented by graduates or masters in sport with the supervision of a sports medicine doctor;~2. Group nutrition counseling, in the form of healthy cooking classes direct by nutritionists with the support of culinary students.
Study NCT01377922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate
Description: Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
Study NCT01151800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using IVR to maintain ACS patients on best practice guidelines
Study NCT01270269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Physical and functional rehabilitation
Description: A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
Study NCT01270269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Cognitive, physical, & functional rehabilitation
Description: A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
Study NCT01377922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
Study NCT01685138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: LDK378/Ceritinib was supplied as 150 mg hard gelatin capsules and administered orally
Study NCT01313286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2608204 Reference
Description: Administered orally
Study NCT01313286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2608204 Test
Description: Administered orally.
Study NCT03210155 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Stim AID CES (Active Comparator)
Description: The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
Study NCT03210155 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Alpha-Stim AID CES (Sham Comparator)
Description: The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
Study NCT02361515 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Moderate hypofractionated radiotherapy
Description: Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.
Study NCT02361515 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.
Study NCT00438880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agatolimod Sodium
Description: Given IV
Study NCT00438880 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Indium In-111 Ibritumomab Tiuxetan
Description: Given IV
Study NCT00438880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative study
Study NCT00438880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo imaging scans
Study NCT00438880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00438880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo imaging scans
Study NCT00438880 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y-90 Ibritumomab Tiuxetan
Description: Given IV
Study NCT04050774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance boards
Description: The unstable surface will be created with a balance board consisting of a wooden board mounted on a section of a cylinder, creating an unstable support in the sagittal plane or in the frontal plane. The participants will stand on three balance boards, varying the height of the surface of the board above the point of contact (15, 17 and 19 cm respectively). The radius of the cylinder will kept constant at 24 cm. The standing surface will be 48cm x 48 cm
Study NCT01146899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Alert
Description: Provider influenza vaccine alert
Study NCT04594070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Iron supplementation
Study NCT04594070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Iron supplementation
Study NCT02601989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Study NCT02601989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Per oral intake of placebo for six weeks
Study NCT03222089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 165 mg/m² 1-hour IV day 1
Study NCT04569630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled hypoglycaemic state while driving
Description: Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Driving data will be recorded in 4 subsequent glycemic states using an adapted hypoglycemic clamp protocol: euglycemia (d1, 5-8 mmol/l), progressive hypoglycaemia (d2, declining from 4.5 to 2.5 mmol/l), stable hypoglycemia (d3, 2.0-2.5 mmol/l), and again in euglycaemia (d4, 5-8 mmol/l). Patients will be blinded to their glucose levels.
Study NCT01258634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexrazoxane
Description: Preoperative Chemotherapy Courses 1, 2, 3, 4: 750mg/m2; IV over 15 minutes on day 1~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 750mg/m2 IV over 15 minutes on Day 1~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 750mg/m2 IV over 15 minutes on Day 1
Study NCT01258634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0